US FDA approves Arrowhead's genetic disorder drug

Core Insights - The U.S. Food and Drug Administration (FDA) has approved Arrowhead Pharmaceuticals' drug for a genetic disorder that leads to extremely high levels of fat in the bloodstream [1] Company Summary - Arrowhead Pharmaceuticals has received FDA approval for its drug targeting a specific genetic disorder [1] Industry Summary - The approval signifies a potential advancement in treatment options for genetic disorders related to lipid metabolism [1]